GSK divests rare disease gene therapy drugs to Orchard Therapeutics – Reuters
PharmaTimes |
GSK divests rare disease gene therapy drugs to Orchard Therapeutics
Reuters LONDON, April 12 (Reuters) – GlaxoSmithKline said on Thursday is was transferring its rare disease gene therapy drugs to Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio … GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics GSK hands rare disease gene therapies over to Orchard |
